Partial Prostatectomy for Prostate Cancer

Launched by INSTITUTO DO CANCER DO ESTADO DE SÃO PAULO · Oct 1, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Partial Prostatectomy for Prostate Cancer," is exploring a surgical option for men with early-stage prostate cancer that is considered to be at an intermediate risk level. The study will involve 50 participants who have been diagnosed with prostate cancer through a specific type of biopsy and have imaging results showing suspicious areas in their prostate. The goal is to assess how safe and feasible this partial surgery is for these patients.

To be eligible for the trial, participants must be men diagnosed with prostate cancer that shows a certain grade in only one side of the prostate. They should have a good chance of living at least 10 more years and must be able to understand and fill out consent forms and questionnaires about their health and quality of life. Participants can expect thorough evaluations and support throughout the study, and they will be contributing to important research that could help improve treatment options for prostate cancer in the future.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with prostate cancer that presents an institutional (ICESP) fusion biopsy (cognitive or target) that presents
• • 1. Fusion-guided prostate biopsy with mpMRI performed at the São Paulo State Cancer Institute, which
• • 2. Present fragments for ISUP group grade (GG) ≤ 3 in only one of the prostate lobes
• • 3. Multiparametric prostate resonance with PIRADS 3 - 5 and which is in agreement with the laterality of the tumor in the prostate biopsy
• • 4. Life expectancy ≥ 10 years according to the Charlson score
• • 5. Absence of second primary cancer under active treatment. Patients treated for cancer from other sites for more than 5 years and without evidence of disease will be allowed
• • 6. Able to read, understand and complete the informed consent related to the research, as well as the research questionnaires on quality of life and functional parameters on erection and urinary continence
• Exclusion Criteria:
• • 1. Patients with prostate cancer with an histology different from adenocarcinoma
• • 2. Suspicion of lymph node metastasis on mpMRI or distant bone scintigraphy
• • 3. definitive signs of extraprostatic extension on mpMRI
• • 4. history of pelvic/prostatic radiotherapy
• • 5. ISUP grade group ≥ 4
• • 6. Laterality of prostate biopsy discordant with mpMRI findings